Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 217

Results For "patients"

3297 News Found

BGS Gleneagles launches its refurbished advanced emergency & trauma center
Healthcare | June 02, 2022

BGS Gleneagles launches its refurbished advanced emergency & trauma center

120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care


FDA approves Roche’s Evrysdi for use in babies under two months with SMA
Drug Approval | June 01, 2022

FDA approves Roche’s Evrysdi for use in babies under two months with SMA

Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date


Ayu Health Hospitals announces t expansion plan in Rajasthan
Healthcare | June 01, 2022

Ayu Health Hospitals announces t expansion plan in Rajasthan

This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.


USFDA accepts dupilumab for priority review in adults with prurigo nodularis
Drug Approval | June 01, 2022

USFDA accepts dupilumab for priority review in adults with prurigo nodularis

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved


US FDA accepts new drug application filed by Avillion for AstraZeneca's PT027
Drug Approval | June 01, 2022

US FDA accepts new drug application filed by Avillion for AstraZeneca's PT027

Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study


LintonPharm to release data on Catumaxomab at ASCO meeting
Biotech | May 30, 2022

LintonPharm to release data on Catumaxomab at ASCO meeting

The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis


USFDA approves Novartis Kymriah CAR-T cell therapy
Biotech | May 29, 2022

USFDA approves Novartis Kymriah CAR-T cell therapy

68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile


Medisca inks distribution license with SUANFARMA
Biotech | May 29, 2022

Medisca inks distribution license with SUANFARMA

Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price


USFDA approves two Opdivo-based regimens
Biotech | May 29, 2022

USFDA approves two Opdivo-based regimens

Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers


MVA-BN respiratory syncytial virus vaccine could get first-to-market opportunity in China, says GlobalData
Biotech | May 29, 2022

MVA-BN respiratory syncytial virus vaccine could get first-to-market opportunity in China, says GlobalData

RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised